Log in
NASDAQ:AKER

Akers Biosciences Stock Forecast, Price & News

$2.21
0.00 (0.00 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.19
Now: $2.21
$2.25
50-Day Range
$2.05
MA: $2.30
$2.55
52-Week Range
$1.55
Now: $2.21
$10.44
Volume65,187 shs
Average Volume1.30 million shs
Market Capitalization$19.28 million
P/E RatioN/A
Dividend YieldN/A
Beta0.23
Akers Biosciences, Inc., together with its subsidiaries, develops, produces, and sells rapid screening and testing products designed to deliver medical devices to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. Its products include BreathScan, a disposable breath alcohol detector; PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol Â'Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek that detects aldehydes or oxidative stress in exhaled human breath. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.71 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKER
CUSIPN/A
Phone856-848-8698
Employees12

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.58 million
Book Value$5.38 per share

Profitability

Net Income$-3,890,000.00
Net Margins-489.84%

Miscellaneous

Market Cap$19.28 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$2.21
0.00 (0.00 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKER News and Ratings via Email

Sign-up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akers Biosciences (NASDAQ:AKER) Frequently Asked Questions

How has Akers Biosciences' stock price been impacted by COVID-19?

Akers Biosciences' stock was trading at $2.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AKER shares have decreased by 2.2% and is now trading at $2.21.
View which stocks have been most impacted by COVID-19
.

When is Akers Biosciences' next earnings date?

Akers Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Akers Biosciences
.

How were Akers Biosciences' earnings last quarter?

Akers Biosciences, Inc. (NASDAQ:AKER) issued its earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share for the quarter. The medical instruments supplier earned $0.56 million during the quarter. Akers Biosciences had a negative return on equity of 107.05% and a negative net margin of 489.84%.
View Akers Biosciences' earnings history
.

Are investors shorting Akers Biosciences?

Akers Biosciences saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 478,200 shares, an increase of 18.7% from the September 15th total of 402,800 shares. Based on an average trading volume of 1,190,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 5.7% of the shares of the company are short sold.
View Akers Biosciences' Short Interest
.

Who are some of Akers Biosciences' key competitors?

What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu BioScience (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL).

Who are Akers Biosciences' key executives?

Akers Biosciences' management team includes the following people:
  • Mr. Christopher C. Schreiber, Exec. Chairman, Principal Exec. Officer & Pres (Age 55, Pay $436k)
  • Mr. Stuart Benson, Chief Financial Officer (Age 59)
  • Mr. Gary M. Rauch, VP of Fin. & Treasurer (Age 64)

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

Who are Akers Biosciences' major shareholders?

Akers Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.15%).
View institutional ownership trends for Akers Biosciences
.

Which major investors are buying Akers Biosciences stock?

AKER stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
View insider buying and selling activity for Akers Biosciences
.

How do I buy shares of Akers Biosciences?

Shares of AKER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $2.21.

How big of a company is Akers Biosciences?

Akers Biosciences has a market capitalization of $19.28 million and generates $1.58 million in revenue each year. Akers Biosciences employs 12 workers across the globe.

What is Akers Biosciences' official website?

The official website for Akers Biosciences is www.akersbio.com.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The medical instruments supplier can be reached via phone at 856-848-8698 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.